Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T45074
|
||||
| Former ID |
TTDI01936
|
||||
| Target Name |
Carnitine acyltransferase
|
||||
| Gene Name |
CRAT
|
||||
| Synonyms |
Carnitine O-acetyltransferase; CAT; Carnitine acetylase; CRAT
|
||||
| Target Type |
Discontinued
|
||||
| Disease | Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | ||||
| Ischemia [ICD9: 459.89; ICD10: I99.8] | |||||
| Function |
Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Plays an important role in triglyceride metabolism.
|
||||
| BioChemical Class |
Acyltransferase
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.3.1.21
|
||||
| Sequence |
MLAFAARTVVKPLGFLKPFSLMKASSRFKAHQDALPRLPVPPLQQSLDHYLKALQPIVSE
EEWAHTKQLVDEFQASGGVGERLQKGLERRARKTENWLSEWWLKTAYLQYRQPVVIYSSP GVMLPKQDFVDLQGQLRFAAKLIEGVLDFKVMIDNETLPVEYLGGKPLCMNQYYQILSSC RVPGPKQDTVSNFSKTKKPPTHITVVHNYQFFELDVYHSDGTPLTADQIFVQLEKIWNSS LQTNKEPVGILTSNHRNSWAKAYNTLIKDKVNRDSVRSIQKSIFTVCLDATMPRVSEDVY RSHVAGQMLHGGGSRLNSGNRWFDKTLQFIVAEDGSCGLVYEHAAAEGPPIVTLLDYVIE YTKKPELVRSPLVPLPMPKKLRFNITPEIKSDIEKAKQNLSIMIQDLDITVMVFHHFGKD FPKSEKLSPDAFIQMALQLAYYRIYGQACATYESASLRMFHLGRTDTIRSASMDSLTFVK AMDDSSVTEHQKVELLRKAVQAHRGYTDRAIRGEAFDRHLLGLKLQAIEDLVSMPDIFMD TSYAIAMHFHLSTSQVPAKTDCVMFFGPVVPDGYGVCYNPMEAHINFSLSAYNSCAETNA ARLAHYLEKALLDMRALLQSHPRAKL |
||||
| Structure |
2LE3
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Teglicar | Drug Info | Discontinued in Phase 2 | Diabetes | [1] |
| LXR-015-2 | Drug Info | Terminated | Ischemia | [2] | |
| Inhibitor | Coenzyme A | Drug Info | [3] | ||
| LXR-015-2 | Drug Info | [4] | |||
| Teglicar | Drug Info | [5] | |||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017026) | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011210) | ||||
| REF 3 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 4 | EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. Brain Res. 2006 Nov 6;1118(1):168-75. Epub 2006 Oct 5. | ||||
| REF 5 | Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes. 2011 February; 60(2): 644-651. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.